MONDAY, May 24, 2021 (HealthDay News) – According to a study published online, high levels of eicosapentaenoic acid (EPA), an omega-3 (ω-3) fatty acid, are not beneficial for patients at high risk for cardiovascular events 16. May at JAMA Cardiology for the American College of Cardiology’s annual meeting, which is practically May 15-17.
Steven E. Nissen, MD of the Cleveland Clinic and colleagues randomly assigned 13,078 high cardiovascular risk patients with elevated triglyceride levels and low levels of high density lipoprotein cholesterol to receive 4 g ω-3-carboxylic acid or an inert comparator daily Corn oil. EPA or docosahexaenoic acid (DHA) plasma levels were assessed at baseline and after 12 months.
The researchers found that the mean plasma levels at 12 months in ω-3-carboxylic acid patients were 89 μg / ml for EPA and 91 μg / ml for DHA, with top-tertile levels of 151 and 118 μg / ml, respectively. The adjusted hazard ratios for cardiovascular events with the highest tertile of plasma levels reached were 0.98 (95 percent confidence interval, 0.83 to 1.16; P = 0.81) for EPA and 1.02 (95 percent confidence interval, Confidence interval, 0.86 to 1.20; P = 0.85) for DHA compared to corn oil. The results were similar in sensitivity analyzes based on changes in plasma and erythrocyte levels of EPA and DHA and for subgroups of primary and secondary prevention.
“Our analysis shows no evidence that high EPA levels have any cardiovascular benefit,” Nissen said in a statement. “Previous studies have shown that fish oil supplements or ikosapentes ethyl help lower triglycerides in people with very high levels of triglycerides. According to current knowledge, however, the overall cardiovascular risk for patients is not reduced. “Several authors announced financial relationships with pharmaceutical companies, including AstraZeneca, which sponsored the study.
Abstract / full text
Copyright © 2021 HealthDay. All rights reserved.